Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Netscientific Appoints Ian Postlethwaite as CFO

5 Apr 2016 07:00

RNS Number : 1367U
NetScientific PLC
05 April 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

 

London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

 

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

 

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

 

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

 

 

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

 

Allergy Therapeutics Italia s.r.l.

 

Allergy Therapeutics Iberia S.L.

 

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

 

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALFFEISRISIIR
Date   Source Headline
18th Jul 20187:00 amRNSWanda Technology Enhancements
26th Jun 20184:24 pmRNSGrant of Options to Directors
21st Jun 20181:33 pmRNSResult of AGM
6th Jun 20187:00 amRNSBob Englert Appointed CEO of Vortex Biosciences
4th Jun 20187:00 amRNSProAxsis Wins Innovative Business of Year in NI
1st Jun 20187:00 amRNSProAxsis Awarded Invest NI Grant
22nd May 20184:21 pmRNSNotice of AGM and Annual Report & Accounts
21st May 20187:00 amRNSWanda Announces Significant Data with Partner HRS
2nd May 20187:00 amRNSProAxsis to Present New Data at ATS 2018
18th Apr 20185:08 pmRNSDirectors Dealing Notification
16th Apr 20182:04 pmRNSResult of General Meeting
16th Apr 20187:25 amRNSVortex to Present 2 Posters at AACR
11th Apr 201811:39 amRNSResult of Placing
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.